Your session is about to expire
← Back to Search
Midodrine for Fainting (POST 4 Trial)
POST 4 Trial Summary
This trial will test whether midodrine prevents fainting in people with a history of fainting.
POST 4 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.POST 4 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have medical conditions that can cause fainting, like heart rhythm problems or low blood pressure when standing up.You have trouble peeing.You have liver disease.You have fainted two or more times in the year before joining the study.You have a syncope symptom score of -2 or higher for structurally normal hearts.You have significant heart problems or irregular heartbeats.You have a heart condition called hypertrophic cardiomyopathy.You have a permanent pacemaker.You have a history of seizures.You have high blood pressure, which is when your blood pressure is higher than 140/90 mm Hg.You have glaucoma.You have been diagnosed with Postural Orthostatic Tachycardia Syndrome or Orthostatic Hypotension based on a 5-minute stand test.
- Group 1: midodrine hydrochloride pills
- Group 2: oral placebo or sugar pill
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What risks are associated with midodrine hydrochloride consumption?
"The safety level of midodrine hydrochloride pills was rated 3, as it is an approved medication and has gone through Phase 4 clinical trials."
How widely distributed are the trials of this treatment across North America?
"Alberta Health Services - Royal Alexandra Hospital in Edmonton, Red Deer Regional Hospital in Red Deer and University of Ottawa Heart Institute in Ottawa are three sites running this clinical trial. Additionally, there are 16 other Canadian medical centres involved."
Are there any antecedent studies that have assessed midodrine hydrochloride tablets?
"Midodrine hydrochloride pills were first investigated in 1997 by the Autonomic Dysfunction Center at Vanderbilt University. Since then, 49 clinical trials have concluded and presently there are 13 active research projects with several based out of Edmonton, Alberta."
Is enrollment for this research endeavor still available?
"Unfortunately, no further participants are being accepted for this trial. Initially posted on November 1st 2011 and last edited on November 1st 2022, it has been ended. However, there are presently 25 clinical trials actively recruiting synocpe patients and 13 studies employing midodrine hydrochloride that require volunteers."
How many individuals are the maximum capacity of this experiment?
"At the moment, this particular research project is not actively recruiting participants. It was first publicly listed on November 1st 2011 and its most recent update occurred on November 1st 2022. If you are looking for other studies related to syncope, there are currently 25 trials that have open enrolment and 13 assessing midodrine hydrochloride tablets in need of volunteers."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger